MTHFD1L and bladder transitional cell carcinoma: In view of the results of our analysis, a significant (P<0.05) overexpression of MTHFD1L was also observed in BLCA, HNSC, KIRP, LUAD, and UCEC patients of different clinicopathological features including different cancer stages, race, gender, and age (Figures 3-7).